Recent Headlines
Within Biotechnology
Creative Diagnostics Launches New Livestock Infectious Diseases Antigens
Creative Diagnostics announced the launch of more than 20 antigens for the development of veterinary infectious diseases diagnostics and vaccines. - August 26, 2022 - Creative Diagnostics
CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods
The Cayman Biomedical Research Institute (CABRI) is offering research grants in amounts up to $100,000 to support essential research on specialized pro-resolving mediator (SPM) analytical methods. - August 26, 2022 - Cayman Chemical Company
Deadline Extended: CABRI Announces Undergraduate Fellowships and Scholarship Program
The Cayman Biomedical Research Institute (CABRI) is accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted from August 22 until September 18, 2022. - August 26, 2022 - Cayman Chemical Company
Pharma CI Conference Returns Next Month: Meet Hundreds of Industry Leaders at the Top Event for 15+ Years
Ready, set, engage! The Pharma CI USA Conference & Exhibition is back in person and ready to deliver the industry-leading experience that has made Pharma CI the gold standard event for more than fifteen years. The much-anticipated return happens this September 21-22 at the Newark Liberty... - August 18, 2022 - Pharma CI Conference
VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC
Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art diagnostic reagents for detection of the abnormal prion associated with Chronic Wasting Disease (CWD). The control of CWD requires identification of... - August 09, 2022 - VMRD, Inc.
Peptineo, LLC Selected by EPA to Provide EPA Nationwide Coverage for Point of Care (POC) COVID-19 Testing
The Environmental Protection Agency (EPA), Cincinnati Acquisition Division (CAD), has awarded Peptineo LLC, an emerging aerospace, health services, and defense solutions company, a three-year Blanket Purchase Agreement (BPA) to support a comprehensive COVID-19 testing program in support of the... - August 07, 2022 - Peptineo
Creative Diagnostics Launches Monkeypox Virus Antibodies and Antigens to Support MPXV Research
Creative Diagnostics announced the launch of several Monkeypox Virus Antibodies and Antigens for the detection of Monkeypox viruses. - July 22, 2022 - Creative Diagnostics
Creative Diagnostics Introduces New Cell-Based ELISA Services
Creative Diagnostics is offering comprehensive services for Cell-based ELISA that can measure the reduction of viral antigens in infected cells using anti-virus antibodies or compounds. - July 22, 2022 - Creative Diagnostics
PharmStars Announces Spring 2022 Accelerator Graduates: 11 Digital Health Startups Have Successfully Completed PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - July 12, 2022 - PharmStars
Global Cancer Technology Successfully Concludes Glioblastoma Pre-Clinical Animal Studies with Impressive Results
Global Cancer Technology, a San Diego, CA biotechnology company, has successfully completed animal testing with GCT.GLIO.1, a PI3K selective inhibitor that can cross the blood brain barrier and modulate immune cell function. The company will advance the compound to Phase 1 clinical trials as a next step. - July 08, 2022 - Global Cancer Technology
PharmStars Announces “Innovations in Real-World Evidence” Theme for Fall 2022 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, announces it is now accepting applications for its Fall 2022 cohort with the theme, “Innovations in Real-World Evidence.” - June 15, 2022 - PharmStars
Defined Bioscience Announces Formation of Scientific Advisory Board
Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the... - June 15, 2022 - Defined Bioscience Inc.
Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies
Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics
Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety
Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics
PharmStars Announces Showcase Pitch Event for Spring 2022 Cohort
PharmStars, the pharma-focused accelerator for digital health startups, announces the start of its Showcase Event on June 8, 2022. The digital health startups that participated in the 10-week accelerator program will make formal presentations to, and answer questions from, the pharma members of PharmStars. All of PharmStars’ seven members are participating in the Showcase Event. - June 08, 2022 - PharmStars
Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) – a Drug Invented at ALS TDI
Eledon Pharmaceuticals announced topline results from their Phase 2 trial of tegoprubart (formerly AT1501), a drug invented and developed at the ALS Therapy Development Institute (ALS TDI). The Phase 2a trial in ALS was a 12-week, open label, dose escalating, safety, and biomarker study. The... - May 31, 2022 - ALS Therapy Development Institute
Scientific Reports Publishes Data Demonstrating VR Platform Produces Peak Experiences, Ego Attenuation & Connectedness Comparable to Moderate Dose Psychedelics
aNUma, Inc., a digital therapeutics company building virtual reality programs to address the global mental health crisis, today, announced that Scientific Reports has published research demonstrating technology like that behind aNUma’s VR platform can deliver peak experiences, ego attenuation, and connectedness comparable to psychedelics. This study, written by Dr. David Glowacki and colleagues, is the first of its kind to be published in a leading peer-reviewed journal. - May 30, 2022 - aNUma
Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services
Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics
Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests
Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics
ALS Therapy Development Institute Scientists to Present Posters Sharing Research Advancements at the ALS Drug Development Summit
The ALS TDI scientists will be showcasing significant advancements in ALS research through multiple poster presentations. These posters will cover pre-clinical research exploring potential new therapeutic drug-like molecules and targets for ALS, as well as translational research analyzing patient data to identify new ALS biomarkers, drug targets, and patient populations. - May 25, 2022 - ALS Therapy Development Institute
Molekule Consulting Announces the Launch of E.U. - Based Operations
Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting
Biopharma Industry Standout Robert Proulx Joins Advisory Board of Global Cancer Technology
Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To date, Mr. Robert Proulx has held numerous Board positions, is a recognized thought leader in biopharma, and currently holds dual roles as the founder and CEO of Imagion Biosystems. - May 21, 2022 - Global Cancer Technology
NuvOx Pharma Announces Issuance of a New Patent
NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Therapeutics
NuvOx Appoints Dr. Robert King to SAB
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Therapeutics
The ALS TDI Discovery Biology Suite Dedicated in Honor of Liz Bodine to Speed Drug Development in ALS
The ALS Therapy Development Institute (ALS TDI) and Augie’s Quest to Cure ALS are proud to honor the commitment of Liz Bodine to facilitate more effective ALS drug discovery at ALS TDI, the world’s most comprehensive drug discovery lab dedicated solely to ALS. - May 04, 2022 - ALS Therapy Development Institute
Cyclists Support ALS Research with 3-Day, 270-Mile Ride from Boston to Greenwich in Tri-State Trek
Hundreds of riders to join the ride to end ALS this June and raise funds for cutting-edge ALS research. ALS TDI has received a $100,000 match for all donations made to the Tri-State Trek through the month of May. - May 03, 2022 - ALS Therapy Development Institute
Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies
Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. - April 30, 2022 - Creative Diagnostics
“Fight ALS Film Fest” Aims to Shine a Spotlight on the World of ALS
Films explore universal themes of life-changing diseases through examination of ALS. Films and dialogue aim to improve understanding, uplift those affected, and expand the community. - April 25, 2022 - ALS Therapy Development Institute
American Laboratory Products Company Merges with GeneProof
American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader... - April 21, 2022 - ALPCO
Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100
Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics, Inc.
NuvOx Technology Featured in Prominent Peer Review Journal
NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022 - NuvOx Therapeutics
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022 - NuvOx Therapeutics
Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health
Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank
Biolexis Therapeutics Announces Poster Presentation at AACR 2022 Annual Meeting
Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at... - April 11, 2022 - Biolexis Therapeutics Inc.
Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100
MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics, Inc.
Instant Systems Expands Its Footprint in Virginia
Instant Systems continues to expand their footprint in Southeast Virginia with the launch of their Central Supply and Order Fulfilment Center (N3) in Virginia Beach, VA. Increased demand for Instant Systems’ products and services is driving the need for more warehouse, production and R&D... - April 07, 2022 - Instant Systems
Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens
Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens. - March 31, 2022 - Creative Diagnostics
New Product for Solar Cells from Solaris Chem (Canada)
Solaris Chem expands its product offering for solar cell applications. - March 19, 2022 - Solaris Chem Inc.
Solaris Chem Products Are Now Available in Germany Through Hözel
Their distribution partner in Germany, Hözel, has included Solaris Chem's products to its range for the biotechnology sector. Hözel has been a well-established company since its foundation in 1993. Thanks to its long-standing market presence, it has a lot of experience and knowledge in... - March 19, 2022 - Solaris Chem Inc.
ALPCO Announced Its Support of the Ukrainian People in a Company-Wide Communication to Its Employees
ALPCO (Salem, NH) announced its support of the Ukrainian people in a company-wide communication to its employees. The message outlined the company's contribution to aid refugees through the American Red Cross and Project Hope in the amount of $5,000 each. Additionally, ALPCO is offering an... - March 16, 2022 - ALPCO
NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program
On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Therapeutics
Thrivous Introduces Personalized Medicine Coaching
Thrivous, the human enhancement company, has partnered with Consolidated Health Solutions to provide personalized medicine coaching. Thrivous' mission is to help customers access technology with the greatest potential to improve their brains and bodies. Customers may achieve better results when... - March 03, 2022 - Thrivous
Locus Fermentation Solutions Selected for Evolution of Manufacturing Award by Smart Business Magazine
Northeast Ohio startup recognized for its innovative biological manufacturing with a near-zero carbon footprint. - February 27, 2022 - Locus Fermentation Solutions
FOXG1 Research Foundation Hosts Napa Valley Charity Golf Tournament to Accelerate Research for Pediatric Neurological Disorder
Scientists believe FOXG1 may hold the key to unlocking brain disorders affecting millions, including autism, Alzheimer’s, brain tumors and more. - February 23, 2022 - FOXG1 Research Foundation
Timothy Healey Joins the Board of Director at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics, Inc.
NuvOx to Participate in the BIO CEO Investor Conference
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Therapeutics
FOXG1 Research Foundation’s Hourinaz Behesti PhD to Present at BIO CEO & Investor Conference 2022
The FOXG1 Research Foundation, the rare disease patient organization that is driving the science to find treatments for FOXG1 syndrome, will be presenting at the BIO CEO & Conference on February 14 to discuss Tapping into Therapeutic Development for Rare CNS Disorders. Dir. of Science, Hourinaz Behesti will discuss why FOXG1 is a viable target for biotech investment, and the suite of assets that the FRF has developed and characterized to help accelerate drug development. - February 09, 2022 - FOXG1 Research Foundation
ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit
ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics, Inc.
Bioplastics International Launches Water Soluble PVA Replacement for Plastics
Bioplastics International creates water soluble PVA products to replace plastics, to stop the plastic pollution of our oceans and beaches. - February 07, 2022 - Bioplastics International
Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics, Inc.